The FDA recently released draft guidance introducing a “plausible mechanism framework,” a new regulatory pathway designed to accelerate approval ofindividualized therapies for ultra-rare diseases. The framework allows sponsors to rely on strong biological rationale, limited patient data, and alternative evidencesources (e.g., natural history or external controls) in place of traditionalrandomized clinical trials, particularly in settings where small patient populationsmake conventional trials infeasible.

The FDA recently granted approvals to two novel therapies targeting ultra-rare pediatric diseases, highlighting continued momentum in gene and enzyme-based innovation. DenaliTherapeutics received accelerated approval for Avlayah, the first new treatment in ~20 years for Hunter syndrome and the firstenzyme therapy to cross the blood-brain barrier, addressingneurological symptoms based on biomarker endpoints.Meanwhile, Rocket Pharmaceuticals secured approval for Kresladi, the first gene therapy for Leukocyte AdhesionDeficiency-I (LAD-I), a life-threatening immune disorder. Launch is expected in Q4 2026 with logistical hurdles limiting uptake.

Aurora Therapeutics launched with the goal of scaling personalized gene editing treatments for rare diseases, building on recent proof-of-conceptsuccesses such as bespoke CRISPR therapies designed for individual patients.The company aims to industrialize this approach by using a platform model leveraging base editing and modular guide RNAs to rapidly create multiple therapies targeting different mutations within the same disease (e.g., PKU).Aurora is poised to rely on the new FDA plausible mechanism framework.

The FDA placed clinical holds on multiple rare disease gene therapy programs in early 2026, including REGENXBIO’s RGX-111 and RGX-121, and Intellia’sCRISPR-based therapy, which has been resumed. These events highlightincreasing regulatory caution around long-term safety risks associated with gene editing and viral vector-based therapies. Recent data suggests ~84% ofinvestors have reduced or paused investment in the space, with many biotechsstruggling to raise capital as regulatory expectations become less predictable.

A coalition of patient groups and biotech executives recently penned a letterurging the Trump administration to “restore regulatory clarity” for rare disease therapies, citing growing concern over shifting and inconsistent FDA expectations.Despite new initiatives aimed at accelerating development, recent regulatory decisions have introduced uncertainty, with similar therapies facing differingrequirements around trial design, surrogate endpoints, and evidence thresholds.Stakeholders note that this lack of predictability is complicating developmentplanning and increasing risk for sponsors navigating already complex rare disease programs.

Ultragenyx announced that the FDA has accepted the resubmission of its BLA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A which is a rare, fatal neurodegenerative disorder with no approved treatments. Theresubmission follows a 2025 CRL driven by manufacturing and facility concerns, and now includes updated long-term clinical data demonstrating durable neurologic and biomarker improvements. The application is under Priority Review, with a potential decision expected in Q3 2026.